A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1386
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. MF
2016 Application of mutant JAK2V617F for in vitro generation of red blood cells. EPO, HSCs, mJAK2, RBCs, wJAK2
2016 Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. ET, MPNs, PMF, TNF-alpha
2016 Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. ET, MPN, PMF
2016 Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. CLL, ET, MPN, PMF
2016 Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. ET, NAP
2016 Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? ET, PMF
2016 Construction of polycythemia vera protein interaction network and prediction of related biological functions. OMIM
2016 Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. CI, HC, HR
10  2016 Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. CI, ET, HT, MPN
11  2016 Idiopathic erythrocytosis: a study of a large cohort with a long follow-up. FE, IE
12  2016 Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). ET, RT-PCR
13  2016 JAK-2 V617F mutation increases heparanase procoagulant activity. CML, ET, PMF, TF, TFPI
14  2016 Management of polycythaemia vera: a critical review of current data. ---
15  2016 Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. BCSH
16  2016 Molecular biomarkers of thrombosis in myeloproliferative neoplasms. CALR, ET, IPSET-Thrombosis, MPN, PMF
17  2016 Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. ET, MF, MPN, MPNs, QOL
18  2016 Myeloproliferative neoplasms: A decade of discoveries and treatment advances. CALR, CML, ET, MPL, MPN, PMF, WHO
19  2016 Myeloproliferative neoplasms: Current molecular biology and genetics. ASXL1, CALR, CBL, DNMT3A, ET, EZH2, HMGA2, IKZF1, MPNs, Ph-MPNs, PMF, SOCS, TET2, TP53
20  2016 Myeloproliferative neoplasms: Morphology and clinical practice. BM, ET, MPNs, prePMF
21  2016 New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. ET, MF, MPN
22  2016 Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. CALR, ET, JAK2, MF, MPNs, PEG-IFN, PET, PPV
23  2016 Polycythemia is associated with bone loss and reduced osteoblast activity in mice. EPO, rEPO, WT
24  2016 Recurrent Stroke with Rapid Development of Intracranial Stenoses in Polycythemia Vera. ---
25  2016 Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. ET, NMSC, OR
26  2016 Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. AER, SEER, SIR, SPM
27  2016 Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. HU, MPN, SAF, TSS
28  2016 The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. CML, ET, MPN, PMF
29  2016 Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? AML, HU
30  2016 [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients]. ET, MPN, MPN-SAF-TSS, PMF
31  2015 A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. CALR, CML, ET, HES, MPNs, PMF
32  2015 Acute Non-Atherosclerotic ST-Segment Elevation Myocardial Infarction in an Adolescent with Concurrent Hemoglobin H-Constant Spring Disease and Polycythemia Vera. STEMI
33  2015 Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. HU
34  2015 Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms. ET, IMF, MPNs
35  2015 Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ET, MIAs
36  2015 Association of the ACE I/D gene polymorphisms with JAK2V617F-positive polycythemia vera and essential thrombocythemia. CG, CI, ET, OR, TG
37  2015 BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms. ET, Ph- MPN, PMF
38  2015 Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. AML, ET, MF
39  2015 CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. APMF, ET, MPN-U, MPNs, PMF
40  2015 Calreticulin exon 9 mutations in myeloproliferative neoplasms. CALR, ET, JAK2, MPL, MPNs, PMF
41  2015 Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. CALR, cloud-like, ECMP, EMGM, ET, MF, MPN, PMGM, PVSG
42  2015 Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. ET, MPNs, PMF
43  2015 Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. ET, JAK2, MPNs, Ph, PMF
44  2015 Concurrent Ruptured Pseudoaneurysm of the Internal Carotid Artery and Cerebral Infarction as an Initial Manifestation of Polycythemia Vera. ICA
45  2015 Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. ET, MF
46  2015 Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? CAD, CFR, ET
47  2015 Current and future treatment options for polycythemia vera. JAK2
48  2015 Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. CML, ET, MPN, PMF, SM
49  2015 Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. ET, MPNs, PMF, SVT
50  2015 Distribution of lymphocyte subpopulations in patients with polycythemia vera. NK
51  2015 Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. 3'UTR, ET, HMGA2, MPNs, PMF
52  2015 Endovascular stent graft repair of thoracic aortic mural thrombus in a patient with polycythemia vera: a word of caution. TAMT
53  2015 Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. BM, ET
54  2015 Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. HU, IFN
55  2015 Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings. ET, miRNA
56  2015 Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. BM, ET, FCI, MDS, MPN, MPN-U, PMF
57  2015 From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. ET, MF, MPNs, Ph
58  2015 Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. AML, CMML, CN-LOH, ET, MC, MDS/MPN, MF, MPN, MPN-U, SNP-A
59  2015 Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis. ET, MPNs, PMF
60  2015 Hyperbaric oxygen therapy in treating post-ischemic pain caused by polycythemia vera complications: a case report. ---
61  2015 Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. ET, JAK, MF, PMF
62  2015 Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. post-PV MF
63  2015 Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders. ET, PMI, RR
64  2015 JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients. CMPNs, ET, PMF
65  2015 JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. MPN, PPMF, PTMF
66  2015 Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. ET, MF, MPNs, PMF
67  2015 Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. AML, BCS, ET, MPN, OLT, PMF
68  2015 Management of symptoms in polycythemia vera and essential thrombocythemia patients. ET, MF, MPNs
69  2015 Massive intracardiac thrombosis during coronary artery bypass grafting surgery. ---
70  2015 Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases: A STROBE-Compliant Observational Study. ECM, ET, MMPs, SP
71  2015 Mechanisms of thrombogenesis in polycythemia vera. ---
72  2015 Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. ET, MPNs, PMF
73  2015 MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia. ET, miRNA, PMF
74  2015 MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. ET, MMPs, MPDs, PCR-RFLP
75  2015 Molecular genetic evaluation of myeloproliferative neoplasms. CML, ET, MPNs, PMF
76  2015 Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. IFN-alpha
77  2015 MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. ET, MF, MPNs
78  2015 Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. ET, MPN-T
79  2015 Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. MPN, MPN-SAF, PMF
80  2015 Myeloproliferative Neoplasms: A Contemporary Review. ASXL1, CALR, ET, JAK2, MPL, PMF
81  2015 Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization. ---
82  2015 New Therapeutic Approaches in Polycythemia Vera. JAK
83  2015 No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation. ET, MPN
84  2015 Novel and emerging therapies for the treatment of polycythemia vera. ---
85  2015 Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. ET, HPF, NF-E2, NGFR
86  2015 Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. ET, VKA
87  2015 Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. HU
88  2015 Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. ---
89  2015 Perioperative blood product administration and thromboembolic events in patients with treated polycythemia vera: a case-control study. CI, OR
90  2015 Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. AVWS, CALR, ET, JAK2, MPL
91  2015 Polycythemia Vera Diagnosed after Esophageal Variceal Rupture. ---
92  2015 Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. ---
93  2015 Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. ET
94  2015 Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. ET, IMF, MPDs, NCI
95  2015 Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. ET, MPNs, PMF
96  2015 Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. BM, ET, MPN, PMF, WHO
97  2015 Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms. ddPCR, ET, MPNs, PMF, SMF
98  2015 Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. ET, IM, miRs, MPNs
99  2015 Ruxolitinib for the treatment of patients with polycythemia vera. ---
100  2015 Ruxolitinib: A Review in Polycythaemia Vera. JAK, STAT